{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063990","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.939319+00:00","generated_at":"2026-05-22T11:57:29.796880+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corbus Pharma Q1 net loss $17M; pipeline on track for data in H2 2025","bullets":["Net loss of $17.0M ($1.39/share) vs $6.9M ($0.83) in Q1 2024; operating expenses rose to $19.8M.","Cash and investments $132.8M; expected to fund operations through Q2 2027.","CRB-701 Nectin-4 ADC dose optimization ongoing; RP2D expected Q4 2025; FDA Fast Track for cervical cancer.","CRB-913 CB1 inverse agonist Phase 1 SAD/MAD started March 2025; completion Q3 2025; Phase 1b starts Q4 2025.","CRB-601 anti-αvβ8 mAb Phase 1 dose escalation ongoing; completion expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063990","json":"https://secwatch.observer/filing/0000950170-25-063990.json","markdown":"https://secwatch.observer/filing/0000950170-25-063990.md","text":"https://secwatch.observer/filing/0000950170-25-063990.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017025063990/0000950170-25-063990-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017025063990/crbp-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:57:29.796880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}